Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
Open Access
- 1 December 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Infection and Drug Resistance
- Vol. ume 13, 4673-4695
- https://doi.org/10.2147/idr.s289037
Abstract
A novel coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, and quickly spread globally. Several treatments have been proposed, many of which have proven ineffective. Consequently, there is a need to review the published evidence of drug clinical trials to guide future prescribing. A systematic review of published clinical trials and retrospective observational studies was carried out. The search was made using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Articles published between January 2020 and October 2020 and written in the English language were retrieved and included in the study. Researches that used traditional medicine, in-vitro and in-vivo animal studies, as well as reviews were excluded. Seventy-three relevant articles that fulfilled the inclusion criteria were finally selected and reviewed. Hydroxychloroquine, chloroquine, and azithromycin produced no clinical evidence of efficacy in randomized controlled clinical trials (RCT). However, retrospective observational studies reported the efficacy of remdesivir and lopinavir/ritonavir in reducing viral load, although there have been concerns with lopinavir/ritonavir and, more recently, remdesivir. Recently, tocilizumab, dexamethasone, and methylprednisolone significantly relieved lung inflammation and decreased mortality in patients with severe COVID-19. In addition, convalescent plasma was effective in boosting strong immunity among patients with mild COVID-19. There is currently no single worldwide approved therapeutic option for patients with COVID-19 despite the initial hype with medicines, including hydroxychloroquine. Nonetheless, dexamethasone has shown promise in symptomatic treatment and convalescent plasma in boosting immunity. New treatments are currently being researched, and the findings will be reported accordingly to provide evidence-based guidance for prescribers and policymakers.Keywords
This publication has 152 references indexed in Scilit:
- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trialThe Lancet Respiratory Medicine, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Estimating excess length of stay due to healthcare-associated infections: a systematic review and meta-analysis of statistical methodologyJournal of Hospital Infection, 2018
- Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysisTherapeutic Advances in Endocrinology and Metabolism, 2018
- Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy ImplicationsThe Patient - Patient-Centered Outcomes Research, 2018
- Coronaviruses: An Overview of Their Replication and PathogenesisPublished by Springer Science and Business Media LLC ,2015
- Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic ReviewApplied Health Economics and Health Policy, 2014